What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Asthma
- Disease
His primary scientific interests are in Asthma, Internal medicine, Placebo, Allergy and Immunology.
His studies deal with areas such as Anesthesia, Clinical trial, Intention-to-treat analysis and Lebrikizumab as well as Asthma.
His Internal medicine research includes elements of Gastroenterology and Surgery.
His Placebo study integrates concerns from other disciplines, such as Omalizumab, Immunoglobulin E and Clinical endpoint.
His Allergy study incorporates themes from Methacholine, Spirometry and Antihistamine.
His research investigates the link between Immunology and topics such as Inhalation that cross with problems in Airborne allergen.
His most cited work include:
- Lebrikizumab Treatment in Adults with Asthma (1290 citations)
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. (949 citations)
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma (501 citations)
What are the main themes of his work throughout his whole career to date?
Jonathan Corren focuses on Asthma, Internal medicine, Placebo, Immunology and In patient.
He is interested in Dupilumab, which is a field of Asthma.
His Dupilumab research is multidisciplinary, relying on both Exhaled nitric oxide, Quality of life and Asthma control.
His studies link Gastroenterology with Internal medicine.
His Placebo research focuses on Corticosteroid and how it connects with Inhaler.
Jonathan Corren works mostly in the field of Anesthesia, limiting it down to topics relating to Mometasone furoate and, in certain cases, Dry-powder inhaler, as a part of the same area of interest.
He most often published in these fields:
- Asthma (55.60%)
- Internal medicine (42.67%)
- Placebo (24.14%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (42.67%)
- Asthma (55.60%)
- Dupilumab (21.55%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Asthma, Dupilumab, In patient and Placebo.
His Internal medicine research includes themes of Gastroenterology and Omalizumab.
His Asthma study deals with the bigger picture of Immunology.
His study in Dupilumab is interdisciplinary in nature, drawing from both Moderate to severe, Immunoglobulin E and Asthma Control Questionnaire.
His work in Placebo tackles topics such as Adverse effect which are related to areas like Cochrane Library.
His biological study spans a wide range of topics, including Reslizumab and Corticosteroid.
Between 2017 and 2021, his most popular works were:
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma (501 citations)
- Conjunctivitis in dupilumab clinical trials. (96 citations)
- Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. (50 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Asthma
- Disease
Jonathan Corren mainly investigates Internal medicine, Asthma, Dupilumab, Placebo and Omalizumab.
His work on Quality of life, Asthma control and Adverse effect as part of general Internal medicine research is frequently linked to Cost effectiveness, thereby connecting diverse disciplines of science.
His Asthma study combines topics from a wide range of disciplines, such as Post-hoc analysis, Exacerbation, Intensive care medicine and Intention-to-treat analysis.
His research in Exacerbation intersects with topics in Allergic asthma and Medical record.
His Dupilumab study also includes
- Benralizumab which intersects with area such as Reslizumab,
- Asthma Control Questionnaire and related Allergic inflammation, Phases of clinical research, Medical history and Immunoglobulin E,
- Exhaled nitric oxide which intersects with area such as Gastroenterology,
- Cochrane Library together with Rate ratio.
His Placebo research incorporates themes from Minimal clinically important difference, Randomized controlled trial, Clinical trial and Nasal polyps.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
